Bronchitis News and Research

RSS

Bronchitis is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. (For more information on the bronchial tubes and the airways. People who have bronchitis often have a cough that brings up mucus. Mucus is a slimy substance made by the lining of the bronchial tubes. Bronchitis also may cause wheezing (a whistling or squeaky sound when you breathe), chest pain or discomfort, a low fever, and shortness of breath. There are two main types of bronchitis: acute (short term) and chronic (ongoing).

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.12 in the fourth quarter of fiscal 2011.

19 Apr 2011

Novartis NVA23 Phase III trial in COPD achieves primary end point

Sosei Group Corporation announces that NVA237, a long-acting muscarinic antagonist being investigated as a once daily treatment for chronic obstructive pulmonary disease, achieved its primary end point in a Phase III study.

19 Apr 2011

Scientist discovers new molecular mechanism underlying asthma, COPD

Michael Croft, Ph.D., a researcher at the La Jolla Institute for Allergy & Immunology, has discovered a molecule's previously unknown role as a major trigger for airway remodeling, which impairs lung function, making the molecule a promising therapeutic target for chronic asthma, chronic obstructive pulmonary disease and several other lung conditions.

18 Apr 2011

Researchers develop non-steroid based strategy for patients with COPD

Researchers at the Johns Hopkins Bloomberg School of Public Health have developed a non-steroid based strategy for improving the lung's innate immune defense and decreasing inflammation that can be a problem for patients with chronic obstructive pulmonary disease.

15 Apr 2011

Natural disasters can produce major lung problems

A comprehensive new review published in the journal Respirology indicates that lung problems are major causes of morbidity and mortality following natural disasters.

29 Mar 2011

POET-COPD study looks at controlling 'lung attacks' which can lead to increased ER visits

Chronic Obstructive Pulmonary Disease (COPD) is a major cause for hospital stays and emergency room visits across Canada and researchers say minimizing exacerbations or flare-ups of the disease can go a long way to reducing hospitalizations.

25 Mar 2011

Rotech closes private offering of $290M in Senior Notes due 2018

Rotech Healthcare Inc. announced the closing of its previously announced offering of $290 million in aggregate principal amount of Senior Second Lien Notes due 2018.

19 Mar 2011

Test that measures destruction of lung air sacs, could help prevent progression of emphysema

During a regular annual physical exam, blood is usually drawn to check the health of a person's heart, kidneys and liver. Now, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center say a blood test that detects the early development of emphysema -- well before symptoms occur -- may someday also be offered.

12 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

An advisory committee recommended today that the Food and Drug Administration (FDA) approve QAB149 (indacaterol) 75 mcg in the US as a once-daily long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

9 Mar 2011

Journal of Chronic Obstructive Pulmonary Disease becomes official journal of COPD Foundation

COPD: Journal of Chronic Obstructive Pulmonary Disease, the first journal dedicated to publishing a range of research on the impact of COPD, has become the official journal of the COPD Foundation.

5 Mar 2011

Study: Vaccinated children and adolescents are less prone to infectious diseases

May vaccinations put too much strain on or weaken children's immune systems and are therefore harmful? Roma Schmitz and her colleagues from the Robert Koch Institute investigate exactly this research question in the current issue of Deutsches Ärzteblatt International.

4 Mar 2011

FDA approves roflumilast to treat COPD

The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups or worsening of symptoms from severe chronic obstructive pulmonary disease.

1 Mar 2011

New drug approved for COPD by the FDA

The U.S. FDA has approved a new treatment for people with worsening symptoms of severe chronic obstructive pulmonary disease (COPD). COPD affects smokers and the elderly and leads to severe difficulty in breathing, chronic cough and excessive mucus production. An exacerbation can last up to several weeks and result in a decline in lung function and increased risk of death, and it may be associated with severe anxiety, the FDA says.

1 Mar 2011

FDA approves Forest Labs' Daliresp to treat COPD

Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

1 Mar 2011

PHA partners with NORD, EURORDIS to raise global awareness about PH

Pulmonary hypertension is a rare, under-diagnosed disease that can strike people at any time, affecting newborns to the elderly or anyone in between. To raise global awareness of this invisible disease, the Pulmonary Hypertension Association is partnering with the National Organization for Rare Disorders and Rare Diseases Europe on Feb. 28, 2011, to observe Rare Disease Day.

25 Feb 2011

AHRQ: Low-income rural Americans with COPD more likely to be hospitalized

Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

18 Feb 2011

Certain uses of terbutaline could lead to maternal heart problems and death, FDA warns

The U.S. Food and Drug Administration is warning that terbutaline administered by injection or through an infusion pump should not be used in pregnant women for prevention or prolonged (beyond 48-72 hours) treatment of preterm labor due to the potential for serious maternal heart problems and death. In addition, oral terbutaline tablets should not be used for prevention or treatment of preterm labor.

18 Feb 2011

Study: Cigarette smoking linked to mucus overproduction in patients with chronic bronchitis

Cigarette smoking has been linked with overproduction of mucus associated with chronic bronchitis, according to a study conducted by researchers in New Mexico. The study indicates cigarette smoke suppresses a protein that causes the natural death of mucus-producing cells in the airways of bronchitis patients.

17 Feb 2011

Bronchitis News and Research

Further Reading

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Novartis NVA23 Phase III trial in COPD achieves primary end point

Scientist discovers new molecular mechanism underlying asthma, COPD

Researchers develop non-steroid based strategy for patients with COPD

Natural disasters can produce major lung problems

POET-COPD study looks at controlling 'lung attacks' which can lead to increased ER visits

Rotech closes private offering of $290M in Senior Notes due 2018

Test that measures destruction of lung air sacs, could help prevent progression of emphysema

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

Journal of Chronic Obstructive Pulmonary Disease becomes official journal of COPD Foundation

Study: Vaccinated children and adolescents are less prone to infectious diseases

FDA approves roflumilast to treat COPD

New drug approved for COPD by the FDA

FDA approves Forest Labs' Daliresp to treat COPD

PHA partners with NORD, EURORDIS to raise global awareness about PH

AHRQ: Low-income rural Americans with COPD more likely to be hospitalized

Certain uses of terbutaline could lead to maternal heart problems and death, FDA warns

Study: Cigarette smoking linked to mucus overproduction in patients with chronic bronchitis

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News